ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESILTLVFIROMKCYALTRBGCZEEHUPLSK..HRIS..MTNORS..SMMA................JBDM Ver 0.1.63 (23 May 2017) - 1999001/0THIS APPLICATION WAS FILED ON 02-06-2017 AS A DIVISIONAL APPLICATION TO THE APPLICATION MENTIONED UNDER INID CODE 62.3232199CORRECTED EUROPEAN PATENT APPLICATIONA8A220171213W172deBibliographieenBibliographyfrBibliographieEP17174222.42015081720170602enenen201416659320140819JP201508555620150420JP201712132017502017101820174220171213201750G01N 33/574 20060101AFI20170904BHEP G01N 33/564 20060101ALI20170904BHEP G01N 33/569 20060101ALI20170904BHEP deVERFAHREN ZUR ERHÖHUNG DER IMMUNZELLENFUNKTION UND VERFAHREN ZUR BEURTEILUNG DER MULTIFUNKTIONALITÄT VON IMMUNZELLENenMETHOD FOR ENHANCING IMMUNE CELL FUNCTION AND METHOD FOR ASSESSING IMMUNE CELL MULTIFUNCTIONALITYfrPROCÉDÉ D'AMÉLIORATION DE LA FONCTION DES CELLULES IMMUNITAIRES ET PROCÉDÉ D'ÉVALUATION DE LA MULTIFONCTIONNALITÉ DES CELLULES IMMUNITAIRESNONE15833898.8319251720150817National University Corporation Okayama University101592874197 942 a/jme1-1, Tsushima-naka 1-chomeKita-ku Okayama-shi Okayama 700-8530JPONO PHARMACEUTICAL CO., LTD.100192365197 942 a/jme1-5, Doshomachi 2-chome Chuo-kuOsaka-shi, Osaka 541-8526JPUDONO, Heiichiroc/o NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY 1-1, Tsushima-Naka 1-chome Kita-ku, Okayama-shiOkayama 700-8530JPEIKAWA, Shingoc/o NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY 1-1, Tsushima-Naka 1-chome Kita-ku, Okayama-shiOkayama 700-8530JPTOYOOKA, Shin-ichic/o NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY 1-1, Tsushima-Naka 1-chome Kita-ku, Okayama-shiOkayama 700-8530JPHoffmann Eitle100061036Patent- und Rechtsanwälte PartmbB Arabellastraße 3081925 MünchenDEALATBEBGCHCYCZDEDKEEESFIFRGBGRHRHUIEISITLILTLULVMCMKMTNLNOPLPTRORSSESISKSMTRMA

The present invention provides a method for enhancing immune cell function by activating various immune cells ex vivo and provides immune cells with enhanced function. The invention further provides an immune-related cell multifunctionality evaluation method. A biguanide antidiabetic drug selected from metformin, phenformin, and buformin is capable of enhancing immune cell multifunctionality by increasing CD8+T cells having a high ability to produce IL-2, TNFα, and IFNγ. The immune-related cell multifunctionality may be evaluated by comparing immune cells treated with a biguanide antidiabetic drug selected from metformin, phenformin, and buformin, with control immune cells untreated with the biguanide antidiabetic drug. When the multifunctionality of immune cells treated with the biguanide antidiabetic drug selected from metformin, phenformin, and buformin is determined to be significantly increased compared with the control, it can be evaluated that the sensitivity of the immune cells to the therapeutic agent is improved.